CovidChloroV1, Main, Exploration, bibRecord, 000C40

Safety assessment of drug combinations used in COVID-19 treatment: in silico toxicogenomic data-mining approach.

Identifieur interne : 000C40 ( Main/Exploration ); précédent : 000C39; suivant : 000C41

Safety assessment of drug combinations used in COVID-19 treatment: in silico toxicogenomic data-mining approach.

Auteurs : Katarina Barali [Serbie] ; Dragica Jorgovanovi [Serbie] ; Katarina Živan Evi [Serbie] ; Evica Antonijevi Miljakovi [Serbie] ; Biljana Antonijevi [Serbie] ; Aleksandra Buha Djordjevic [Serbie] ; Marijana Ur I [Serbie] ; Danijela Uki Osi [Serbie]

Source :

Toxicology and applied pharmacology [ 1096-0333 ] ; 2020.

RBID : pubmed:32920000

Descripteurs français

KwdFr :
- Antiviraux (administration et posologie), Antiviraux (effets indésirables), Association de médicaments (MeSH), Azithromycine (administration et posologie), Azithromycine (effets indésirables), Bases de données génétiques (MeSH), Betacoronavirus (MeSH), Chloroquine (administration et posologie), Chloroquine (effets indésirables), Fouille de données (méthodes), Humains (MeSH), Hydroxychloroquine (administration et posologie), Hydroxychloroquine (effets indésirables), Infections à coronavirus (génétique), Infections à coronavirus (traitement médicamenteux), Lopinavir (administration et posologie), Lopinavir (effets indésirables), Pandémies (MeSH), Pneumopathie virale (génétique), Pneumopathie virale (traitement médicamenteux), Ritonavir (administration et posologie), Ritonavir (effets indésirables), Réseaux de régulation génique (effets des médicaments et des substances chimiques), Réseaux de régulation génique (génétique), Simulation numérique (MeSH), Toxicogénétique (méthodes).
MESH :
- administration et posologie : Antiviraux, Azithromycine, Chloroquine, Hydroxychloroquine, Lopinavir, Ritonavir.
- effets des médicaments et des substances chimiques : Réseaux de régulation génique.
- effets indésirables : Antiviraux, Azithromycine, Chloroquine, Hydroxychloroquine, Lopinavir, Ritonavir.
- génétique : Infections à coronavirus, Pneumopathie virale, Réseaux de régulation génique.
- méthodes : Fouille de données, Toxicogénétique.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- Association de médicaments, Bases de données génétiques, Betacoronavirus, Humains, Pandémies, Simulation numérique.

English descriptors

KwdEn :
- Antiviral Agents (administration & dosage), Antiviral Agents (adverse effects), Azithromycin (administration & dosage), Azithromycin (adverse effects), Betacoronavirus (MeSH), COVID-19 (MeSH), Chloroquine (administration & dosage), Chloroquine (adverse effects), Computer Simulation (MeSH), Coronavirus Infections (drug therapy), Coronavirus Infections (genetics), Data Mining (methods), Databases, Genetic (MeSH), Drug Therapy, Combination (MeSH), Gene Regulatory Networks (drug effects), Gene Regulatory Networks (genetics), Humans (MeSH), Hydroxychloroquine (administration & dosage), Hydroxychloroquine (adverse effects), Lopinavir (administration & dosage), Lopinavir (adverse effects), Pandemics (MeSH), Pneumonia, Viral (drug therapy), Pneumonia, Viral (genetics), Ritonavir (administration & dosage), Ritonavir (adverse effects), SARS-CoV-2 (MeSH), Toxicogenetics (methods).
MESH :
- chemical , administration & dosage : Antiviral Agents, Azithromycin, Chloroquine, Hydroxychloroquine, Lopinavir, Ritonavir.
- chemical , adverse effects : Antiviral Agents, Azithromycin, Chloroquine, Hydroxychloroquine, Lopinavir, Ritonavir.
- drug effects : Gene Regulatory Networks.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- genetics : Coronavirus Infections, Gene Regulatory Networks, Pneumonia, Viral.
- methods : Data Mining, Toxicogenetics.
- Betacoronavirus, COVID-19, Computer Simulation, Databases, Genetic, Drug Therapy, Combination, Humans, Pandemics, SARS-CoV-2.

Abstract

Improvement of COVID-19 clinical condition was seen in studies where combination of antiretroviral drugs, lopinavir and ritonavir, as well as immunomodulant antimalaric, chloroquine/hydroxychloroquine together with the macrolide-type antibiotic, azithromycin, was used for patient's treatment. Although these drugs are "old", their pharmacological and toxicological profile in SARS-CoV-2 - infected patients are still unknown. Thus, by using in silico toxicogenomic data-mining approach, we aimed to assess both risks and benefits of the COVID-19 treatment with the most promising candidate drugs combinations: lopinavir/ritonavir and chloroquine/hydroxychloroquine + azithromycin. The Comparative Toxicogenomics Database (CTD; http://CTD.mdibl.org), Cytoscape software (https://cytoscape.org) and ToppGene Suite portal (https://toppgene.cchmc.org) served as a foundation in our research. Our results have demonstrated that lopinavir/ritonavir increased the expression of the genes involved in immune response and lipid metabolism (IL6, ICAM1, CCL2, TNF, APOA1, etc.). Chloroquine/hydroxychloroquine + azithromycin interacted with 6 genes (CCL2, CTSB, CXCL8, IL1B, IL6 and TNF), whereas chloroquine and azithromycin affected two additional genes (BCL2L1 and CYP3A4), which might be a reason behind a greater number of consequential diseases. In contrast to lopinavir/ritonavir, chloroquine/hydroxychloroquine + azithromycin downregulated the expression of TNF and IL6. As expected, inflammation, cardiotoxicity, and dyslipidaemias were revealed as the main risks of lopinavir/ritonavir treatment, while chloroquine/hydroxychloroquine + azithromycin therapy was additionally linked to gastrointestinal and skin diseases. According to our results, these drug combinations should be administrated with caution to patients suffering from cardiovascular problems, autoimmune diseases, or acquired and hereditary lipid disorders.

DOI: 10.1016/j.taap.2020.115237
PubMed: 32920000
PubMed Central: PMC7483129

Affiliations:

Serbie

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000C38
to stream Main, to step Curation: 000C38

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Safety assessment of drug combinations used in COVID-19 treatment: in silico toxicogenomic data-mining approach.</title>
<author><name sortKey="Barali, Katarina" sort="Barali, Katarina" uniqKey="Barali K" first="Katarina" last="Barali">Katarina Barali</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Toxicology "Akademik Danilo Soldatović", Center for Toxicological Risk Assessment, University of Belgrade - Faculty of Pharmacy, Serbia. Electronic address: katarinab@pharmacy.bg.ac.rs.</nlm:affiliation>
<country xml:lang="fr">Serbie</country>
<wicri:regionArea>Department of Toxicology "Akademik Danilo Soldatović", Center for Toxicological Risk Assessment, University of Belgrade - Faculty of Pharmacy</wicri:regionArea>
<wicri:noRegion>University of Belgrade - Faculty of Pharmacy</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Jorgovanovi, Dragica" sort="Jorgovanovi, Dragica" uniqKey="Jorgovanovi D" first="Dragica" last="Jorgovanovi">Dragica Jorgovanovi</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Toxicology "Akademik Danilo Soldatović", Center for Toxicological Risk Assessment, University of Belgrade - Faculty of Pharmacy, Serbia.</nlm:affiliation>
<country xml:lang="fr">Serbie</country>
<wicri:regionArea>Department of Toxicology "Akademik Danilo Soldatović", Center for Toxicological Risk Assessment, University of Belgrade - Faculty of Pharmacy</wicri:regionArea>
<wicri:noRegion>University of Belgrade - Faculty of Pharmacy</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Zivan Evi, Katarina" sort="Zivan Evi, Katarina" uniqKey="Zivan Evi K" first="Katarina" last="Živan Evi">Katarina Živan Evi</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Toxicology "Akademik Danilo Soldatović", Center for Toxicological Risk Assessment, University of Belgrade - Faculty of Pharmacy, Serbia.</nlm:affiliation>
<country xml:lang="fr">Serbie</country>
<wicri:regionArea>Department of Toxicology "Akademik Danilo Soldatović", Center for Toxicological Risk Assessment, University of Belgrade - Faculty of Pharmacy</wicri:regionArea>
<wicri:noRegion>University of Belgrade - Faculty of Pharmacy</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Antonijevi Miljakovi, Evica" sort="Antonijevi Miljakovi, Evica" uniqKey="Antonijevi Miljakovi E" first="Evica" last="Antonijevi Miljakovi">Evica Antonijevi Miljakovi</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Toxicology "Akademik Danilo Soldatović", Center for Toxicological Risk Assessment, University of Belgrade - Faculty of Pharmacy, Serbia. Electronic address: evica.antonijevic@pharmacy.bg.ac.rs.</nlm:affiliation>
<country xml:lang="fr">Serbie</country>
<wicri:regionArea>Department of Toxicology "Akademik Danilo Soldatović", Center for Toxicological Risk Assessment, University of Belgrade - Faculty of Pharmacy</wicri:regionArea>
<wicri:noRegion>University of Belgrade - Faculty of Pharmacy</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Antonijevi, Biljana" sort="Antonijevi, Biljana" uniqKey="Antonijevi B" first="Biljana" last="Antonijevi">Biljana Antonijevi</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Toxicology "Akademik Danilo Soldatović", Center for Toxicological Risk Assessment, University of Belgrade - Faculty of Pharmacy, Serbia. Electronic address: biljana.antonijevic@pharmacy.bg.ac.rs.</nlm:affiliation>
<country xml:lang="fr">Serbie</country>
<wicri:regionArea>Department of Toxicology "Akademik Danilo Soldatović", Center for Toxicological Risk Assessment, University of Belgrade - Faculty of Pharmacy</wicri:regionArea>
<wicri:noRegion>University of Belgrade - Faculty of Pharmacy</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Buha Djordjevic, Aleksandra" sort="Buha Djordjevic, Aleksandra" uniqKey="Buha Djordjevic A" first="Aleksandra" last="Buha Djordjevic">Aleksandra Buha Djordjevic</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Toxicology "Akademik Danilo Soldatović", Center for Toxicological Risk Assessment, University of Belgrade - Faculty of Pharmacy, Serbia. Electronic address: aleksandra.buha@pharmacy.bg.ac.rs.</nlm:affiliation>
<country xml:lang="fr">Serbie</country>
<wicri:regionArea>Department of Toxicology "Akademik Danilo Soldatović", Center for Toxicological Risk Assessment, University of Belgrade - Faculty of Pharmacy</wicri:regionArea>
<wicri:noRegion>University of Belgrade - Faculty of Pharmacy</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey=" Ur I, Marijana" sort=" Ur I, Marijana" uniqKey=" Ur I M" first="Marijana" last=" Ur I">Marijana  Ur I</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Toxicology "Akademik Danilo Soldatović", Center for Toxicological Risk Assessment, University of Belgrade - Faculty of Pharmacy, Serbia. Electronic address: marijana.curcic@pharmacy.bg.ac.rs.</nlm:affiliation>
<country xml:lang="fr">Serbie</country>
<wicri:regionArea>Department of Toxicology "Akademik Danilo Soldatović", Center for Toxicological Risk Assessment, University of Belgrade - Faculty of Pharmacy</wicri:regionArea>
<wicri:noRegion>University of Belgrade - Faculty of Pharmacy</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey=" Uki Osi, Danijela" sort=" Uki Osi, Danijela" uniqKey=" Uki Osi D" first="Danijela" last=" Uki Osi">Danijela  Uki Osi</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Toxicology "Akademik Danilo Soldatović", Center for Toxicological Risk Assessment, University of Belgrade - Faculty of Pharmacy, Serbia. Electronic address: danijela.djukic.cosic@pharmacy.bg.ac.rs.</nlm:affiliation>
<country xml:lang="fr">Serbie</country>
<wicri:regionArea>Department of Toxicology "Akademik Danilo Soldatović", Center for Toxicological Risk Assessment, University of Belgrade - Faculty of Pharmacy</wicri:regionArea>
<wicri:noRegion>University of Belgrade - Faculty of Pharmacy</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32920000</idno>
<idno type="pmid">32920000</idno>
<idno type="doi">10.1016/j.taap.2020.115237</idno>
<idno type="pmc">PMC7483129</idno>
<idno type="wicri:Area/Main/Corpus">000C38</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000C38</idno>
<idno type="wicri:Area/Main/Curation">000C38</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000C38</idno>
<idno type="wicri:Area/Main/Exploration">000C38</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Safety assessment of drug combinations used in COVID-19 treatment: in silico toxicogenomic data-mining approach.</title>
<author><name sortKey="Barali, Katarina" sort="Barali, Katarina" uniqKey="Barali K" first="Katarina" last="Barali">Katarina Barali</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Toxicology "Akademik Danilo Soldatović", Center for Toxicological Risk Assessment, University of Belgrade - Faculty of Pharmacy, Serbia. Electronic address: katarinab@pharmacy.bg.ac.rs.</nlm:affiliation>
<country xml:lang="fr">Serbie</country>
<wicri:regionArea>Department of Toxicology "Akademik Danilo Soldatović", Center for Toxicological Risk Assessment, University of Belgrade - Faculty of Pharmacy</wicri:regionArea>
<wicri:noRegion>University of Belgrade - Faculty of Pharmacy</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Jorgovanovi, Dragica" sort="Jorgovanovi, Dragica" uniqKey="Jorgovanovi D" first="Dragica" last="Jorgovanovi">Dragica Jorgovanovi</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Toxicology "Akademik Danilo Soldatović", Center for Toxicological Risk Assessment, University of Belgrade - Faculty of Pharmacy, Serbia.</nlm:affiliation>
<country xml:lang="fr">Serbie</country>
<wicri:regionArea>Department of Toxicology "Akademik Danilo Soldatović", Center for Toxicological Risk Assessment, University of Belgrade - Faculty of Pharmacy</wicri:regionArea>
<wicri:noRegion>University of Belgrade - Faculty of Pharmacy</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Zivan Evi, Katarina" sort="Zivan Evi, Katarina" uniqKey="Zivan Evi K" first="Katarina" last="Živan Evi">Katarina Živan Evi</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Toxicology "Akademik Danilo Soldatović", Center for Toxicological Risk Assessment, University of Belgrade - Faculty of Pharmacy, Serbia.</nlm:affiliation>
<country xml:lang="fr">Serbie</country>
<wicri:regionArea>Department of Toxicology "Akademik Danilo Soldatović", Center for Toxicological Risk Assessment, University of Belgrade - Faculty of Pharmacy</wicri:regionArea>
<wicri:noRegion>University of Belgrade - Faculty of Pharmacy</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Antonijevi Miljakovi, Evica" sort="Antonijevi Miljakovi, Evica" uniqKey="Antonijevi Miljakovi E" first="Evica" last="Antonijevi Miljakovi">Evica Antonijevi Miljakovi</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Toxicology "Akademik Danilo Soldatović", Center for Toxicological Risk Assessment, University of Belgrade - Faculty of Pharmacy, Serbia. Electronic address: evica.antonijevic@pharmacy.bg.ac.rs.</nlm:affiliation>
<country xml:lang="fr">Serbie</country>
<wicri:regionArea>Department of Toxicology "Akademik Danilo Soldatović", Center for Toxicological Risk Assessment, University of Belgrade - Faculty of Pharmacy</wicri:regionArea>
<wicri:noRegion>University of Belgrade - Faculty of Pharmacy</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Antonijevi, Biljana" sort="Antonijevi, Biljana" uniqKey="Antonijevi B" first="Biljana" last="Antonijevi">Biljana Antonijevi</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Toxicology "Akademik Danilo Soldatović", Center for Toxicological Risk Assessment, University of Belgrade - Faculty of Pharmacy, Serbia. Electronic address: biljana.antonijevic@pharmacy.bg.ac.rs.</nlm:affiliation>
<country xml:lang="fr">Serbie</country>
<wicri:regionArea>Department of Toxicology "Akademik Danilo Soldatović", Center for Toxicological Risk Assessment, University of Belgrade - Faculty of Pharmacy</wicri:regionArea>
<wicri:noRegion>University of Belgrade - Faculty of Pharmacy</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Buha Djordjevic, Aleksandra" sort="Buha Djordjevic, Aleksandra" uniqKey="Buha Djordjevic A" first="Aleksandra" last="Buha Djordjevic">Aleksandra Buha Djordjevic</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Toxicology "Akademik Danilo Soldatović", Center for Toxicological Risk Assessment, University of Belgrade - Faculty of Pharmacy, Serbia. Electronic address: aleksandra.buha@pharmacy.bg.ac.rs.</nlm:affiliation>
<country xml:lang="fr">Serbie</country>
<wicri:regionArea>Department of Toxicology "Akademik Danilo Soldatović", Center for Toxicological Risk Assessment, University of Belgrade - Faculty of Pharmacy</wicri:regionArea>
<wicri:noRegion>University of Belgrade - Faculty of Pharmacy</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey=" Ur I, Marijana" sort=" Ur I, Marijana" uniqKey=" Ur I M" first="Marijana" last=" Ur I">Marijana  Ur I</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Toxicology "Akademik Danilo Soldatović", Center for Toxicological Risk Assessment, University of Belgrade - Faculty of Pharmacy, Serbia. Electronic address: marijana.curcic@pharmacy.bg.ac.rs.</nlm:affiliation>
<country xml:lang="fr">Serbie</country>
<wicri:regionArea>Department of Toxicology "Akademik Danilo Soldatović", Center for Toxicological Risk Assessment, University of Belgrade - Faculty of Pharmacy</wicri:regionArea>
<wicri:noRegion>University of Belgrade - Faculty of Pharmacy</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey=" Uki Osi, Danijela" sort=" Uki Osi, Danijela" uniqKey=" Uki Osi D" first="Danijela" last=" Uki Osi">Danijela  Uki Osi</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Toxicology "Akademik Danilo Soldatović", Center for Toxicological Risk Assessment, University of Belgrade - Faculty of Pharmacy, Serbia. Electronic address: danijela.djukic.cosic@pharmacy.bg.ac.rs.</nlm:affiliation>
<country xml:lang="fr">Serbie</country>
<wicri:regionArea>Department of Toxicology "Akademik Danilo Soldatović", Center for Toxicological Risk Assessment, University of Belgrade - Faculty of Pharmacy</wicri:regionArea>
<wicri:noRegion>University of Belgrade - Faculty of Pharmacy</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Toxicology and applied pharmacology</title>
<idno type="eISSN">1096-0333</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (administration & dosage)</term>
<term>Antiviral Agents (adverse effects)</term>
<term>Azithromycin (administration & dosage)</term>
<term>Azithromycin (adverse effects)</term>
<term>Betacoronavirus (MeSH)</term>
<term>COVID-19 (MeSH)</term>
<term>Chloroquine (administration & dosage)</term>
<term>Chloroquine (adverse effects)</term>
<term>Computer Simulation (MeSH)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Coronavirus Infections (genetics)</term>
<term>Data Mining (methods)</term>
<term>Databases, Genetic (MeSH)</term>
<term>Drug Therapy, Combination (MeSH)</term>
<term>Gene Regulatory Networks (drug effects)</term>
<term>Gene Regulatory Networks (genetics)</term>
<term>Humans (MeSH)</term>
<term>Hydroxychloroquine (administration & dosage)</term>
<term>Hydroxychloroquine (adverse effects)</term>
<term>Lopinavir (administration & dosage)</term>
<term>Lopinavir (adverse effects)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (drug therapy)</term>
<term>Pneumonia, Viral (genetics)</term>
<term>Ritonavir (administration & dosage)</term>
<term>Ritonavir (adverse effects)</term>
<term>SARS-CoV-2 (MeSH)</term>
<term>Toxicogenetics (methods)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Antiviraux (administration et posologie)</term>
<term>Antiviraux (effets indésirables)</term>
<term>Association de médicaments (MeSH)</term>
<term>Azithromycine (administration et posologie)</term>
<term>Azithromycine (effets indésirables)</term>
<term>Bases de données génétiques (MeSH)</term>
<term>Betacoronavirus (MeSH)</term>
<term>Chloroquine (administration et posologie)</term>
<term>Chloroquine (effets indésirables)</term>
<term>Fouille de données (méthodes)</term>
<term>Humains (MeSH)</term>
<term>Hydroxychloroquine (administration et posologie)</term>
<term>Hydroxychloroquine (effets indésirables)</term>
<term>Infections à coronavirus (génétique)</term>
<term>Infections à coronavirus (traitement médicamenteux)</term>
<term>Lopinavir (administration et posologie)</term>
<term>Lopinavir (effets indésirables)</term>
<term>Pandémies (MeSH)</term>
<term>Pneumopathie virale (génétique)</term>
<term>Pneumopathie virale (traitement médicamenteux)</term>
<term>Ritonavir (administration et posologie)</term>
<term>Ritonavir (effets indésirables)</term>
<term>Réseaux de régulation génique (effets des médicaments et des substances chimiques)</term>
<term>Réseaux de régulation génique (génétique)</term>
<term>Simulation numérique (MeSH)</term>
<term>Toxicogénétique (méthodes)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiviral Agents</term>
<term>Azithromycin</term>
<term>Chloroquine</term>
<term>Hydroxychloroquine</term>
<term>Lopinavir</term>
<term>Ritonavir</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiviral Agents</term>
<term>Azithromycin</term>
<term>Chloroquine</term>
<term>Hydroxychloroquine</term>
<term>Lopinavir</term>
<term>Ritonavir</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antiviraux</term>
<term>Azithromycine</term>
<term>Chloroquine</term>
<term>Hydroxychloroquine</term>
<term>Lopinavir</term>
<term>Ritonavir</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Gene Regulatory Networks</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Réseaux de régulation génique</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antiviraux</term>
<term>Azithromycine</term>
<term>Chloroquine</term>
<term>Hydroxychloroquine</term>
<term>Lopinavir</term>
<term>Ritonavir</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Coronavirus Infections</term>
<term>Gene Regulatory Networks</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
<term>Réseaux de régulation génique</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Data Mining</term>
<term>Toxicogenetics</term>
</keywords>
<keywords scheme="MESH" qualifier="méthodes" xml:lang="fr"><term>Fouille de données</term>
<term>Toxicogénétique</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term>
<term>COVID-19</term>
<term>Computer Simulation</term>
<term>Databases, Genetic</term>
<term>Drug Therapy, Combination</term>
<term>Humans</term>
<term>Pandemics</term>
<term>SARS-CoV-2</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Association de médicaments</term>
<term>Bases de données génétiques</term>
<term>Betacoronavirus</term>
<term>Humains</term>
<term>Pandémies</term>
<term>Simulation numérique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Improvement of COVID-19 clinical condition was seen in studies where combination of antiretroviral drugs, lopinavir and ritonavir, as well as immunomodulant antimalaric, chloroquine/hydroxychloroquine together with the macrolide-type antibiotic, azithromycin, was used for patient's treatment. Although these drugs are "old", their pharmacological and toxicological profile in SARS-CoV-2 - infected patients are still unknown. Thus, by using in silico toxicogenomic data-mining approach, we aimed to assess both risks and benefits of the COVID-19 treatment with the most promising candidate drugs combinations: lopinavir/ritonavir and chloroquine/hydroxychloroquine + azithromycin. The Comparative Toxicogenomics Database (CTD; http://CTD.mdibl.org), Cytoscape software (https://cytoscape.org) and ToppGene Suite portal (https://toppgene.cchmc.org) served as a foundation in our research. Our results have demonstrated that lopinavir/ritonavir increased the expression of the genes involved in immune response and lipid metabolism (IL6, ICAM1, CCL2, TNF, APOA1, etc.). Chloroquine/hydroxychloroquine + azithromycin interacted with 6 genes (CCL2, CTSB, CXCL8, IL1B, IL6 and TNF), whereas chloroquine and azithromycin affected two additional genes (BCL2L1 and CYP3A4), which might be a reason behind a greater number of consequential diseases. In contrast to lopinavir/ritonavir, chloroquine/hydroxychloroquine + azithromycin downregulated the expression of TNF and IL6. As expected, inflammation, cardiotoxicity, and dyslipidaemias were revealed as the main risks of lopinavir/ritonavir treatment, while chloroquine/hydroxychloroquine + azithromycin therapy was additionally linked to gastrointestinal and skin diseases. According to our results, these drug combinations should be administrated with caution to patients suffering from cardiovascular problems, autoimmune diseases, or acquired and hereditary lipid disorders.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32920000</PMID>
<DateCompleted><Year>2020</Year>
<Month>10</Month>
<Day>20</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>01</Month>
<Day>10</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-0333</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>406</Volume>
<PubDate><Year>2020</Year>
<Month>11</Month>
<Day>01</Day>
</PubDate>
</JournalIssue>
<Title>Toxicology and applied pharmacology</Title>
<ISOAbbreviation>Toxicol Appl Pharmacol</ISOAbbreviation>
</Journal>
<ArticleTitle>Safety assessment of drug combinations used in COVID-19 treatment: in silico toxicogenomic data-mining approach.</ArticleTitle>
<Pagination><MedlinePgn>115237</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S0041-008X(20)30363-X</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.taap.2020.115237</ELocationID>
<Abstract><AbstractText>Improvement of COVID-19 clinical condition was seen in studies where combination of antiretroviral drugs, lopinavir and ritonavir, as well as immunomodulant antimalaric, chloroquine/hydroxychloroquine together with the macrolide-type antibiotic, azithromycin, was used for patient's treatment. Although these drugs are "old", their pharmacological and toxicological profile in SARS-CoV-2 - infected patients are still unknown. Thus, by using in silico toxicogenomic data-mining approach, we aimed to assess both risks and benefits of the COVID-19 treatment with the most promising candidate drugs combinations: lopinavir/ritonavir and chloroquine/hydroxychloroquine + azithromycin. The Comparative Toxicogenomics Database (CTD; http://CTD.mdibl.org), Cytoscape software (https://cytoscape.org) and ToppGene Suite portal (https://toppgene.cchmc.org) served as a foundation in our research. Our results have demonstrated that lopinavir/ritonavir increased the expression of the genes involved in immune response and lipid metabolism (IL6, ICAM1, CCL2, TNF, APOA1, etc.). Chloroquine/hydroxychloroquine + azithromycin interacted with 6 genes (CCL2, CTSB, CXCL8, IL1B, IL6 and TNF), whereas chloroquine and azithromycin affected two additional genes (BCL2L1 and CYP3A4), which might be a reason behind a greater number of consequential diseases. In contrast to lopinavir/ritonavir, chloroquine/hydroxychloroquine + azithromycin downregulated the expression of TNF and IL6. As expected, inflammation, cardiotoxicity, and dyslipidaemias were revealed as the main risks of lopinavir/ritonavir treatment, while chloroquine/hydroxychloroquine + azithromycin therapy was additionally linked to gastrointestinal and skin diseases. According to our results, these drug combinations should be administrated with caution to patients suffering from cardiovascular problems, autoimmune diseases, or acquired and hereditary lipid disorders.</AbstractText>
<CopyrightInformation>Copyright © 2020 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Baralić</LastName>
<ForeName>Katarina</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>Department of Toxicology "Akademik Danilo Soldatović", Center for Toxicological Risk Assessment, University of Belgrade - Faculty of Pharmacy, Serbia. Electronic address: katarinab@pharmacy.bg.ac.rs.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Jorgovanović</LastName>
<ForeName>Dragica</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Department of Toxicology "Akademik Danilo Soldatović", Center for Toxicological Risk Assessment, University of Belgrade - Faculty of Pharmacy, Serbia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Živančević</LastName>
<ForeName>Katarina</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>Department of Toxicology "Akademik Danilo Soldatović", Center for Toxicological Risk Assessment, University of Belgrade - Faculty of Pharmacy, Serbia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Antonijević Miljaković</LastName>
<ForeName>Evica</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>Department of Toxicology "Akademik Danilo Soldatović", Center for Toxicological Risk Assessment, University of Belgrade - Faculty of Pharmacy, Serbia. Electronic address: evica.antonijevic@pharmacy.bg.ac.rs.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Antonijević</LastName>
<ForeName>Biljana</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>Department of Toxicology "Akademik Danilo Soldatović", Center for Toxicological Risk Assessment, University of Belgrade - Faculty of Pharmacy, Serbia. Electronic address: biljana.antonijevic@pharmacy.bg.ac.rs.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Buha Djordjevic</LastName>
<ForeName>Aleksandra</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Department of Toxicology "Akademik Danilo Soldatović", Center for Toxicological Risk Assessment, University of Belgrade - Faculty of Pharmacy, Serbia. Electronic address: aleksandra.buha@pharmacy.bg.ac.rs.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ćurčić</LastName>
<ForeName>Marijana</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Department of Toxicology "Akademik Danilo Soldatović", Center for Toxicological Risk Assessment, University of Belgrade - Faculty of Pharmacy, Serbia. Electronic address: marijana.curcic@pharmacy.bg.ac.rs.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Đukić-Ćosić</LastName>
<ForeName>Danijela</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Department of Toxicology "Akademik Danilo Soldatović", Center for Toxicological Risk Assessment, University of Belgrade - Faculty of Pharmacy, Serbia. Electronic address: danijela.djukic.cosic@pharmacy.bg.ac.rs.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>09</Month>
<Day>11</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Toxicol Appl Pharmacol</MedlineTA>
<NlmUniqueID>0416575</NlmUniqueID>
<ISSNLinking>0041-008X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>2494G1JF75</RegistryNumber>
<NameOfSubstance UI="D061466">Lopinavir</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber>
<NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>83905-01-5</RegistryNumber>
<NameOfSubstance UI="D017963">Azithromycin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>886U3H6UFF</RegistryNumber>
<NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>O3J8G9O825</RegistryNumber>
<NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017963" MajorTopicYN="N">Azithromycin</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002738" MajorTopicYN="N">Chloroquine</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003198" MajorTopicYN="Y">Computer Simulation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D057225" MajorTopicYN="N">Data Mining</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D030541" MajorTopicYN="N">Databases, Genetic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053263" MajorTopicYN="N">Gene Regulatory Networks</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D061466" MajorTopicYN="N">Lopinavir</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019438" MajorTopicYN="N">Ritonavir</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D043922" MajorTopicYN="N">Toxicogenetics</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Anti-COVID-19 Therapy</Keyword>
<Keyword MajorTopicYN="Y">Azithromycin</Keyword>
<Keyword MajorTopicYN="Y">Chloroquine</Keyword>
<Keyword MajorTopicYN="Y">Lopinavir</Keyword>
<Keyword MajorTopicYN="Y">Ritonavir</Keyword>
<Keyword MajorTopicYN="Y">in silico Approach</Keyword>
</KeywordList>
<CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>05</Month>
<Day>18</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2020</Year>
<Month>07</Month>
<Day>11</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>09</Month>
<Day>08</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>9</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>10</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>9</Month>
<Day>13</Day>
<Hour>20</Hour>
<Minute>29</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32920000</ArticleId>
<ArticleId IdType="pii">S0041-008X(20)30363-X</ArticleId>
<ArticleId IdType="doi">10.1016/j.taap.2020.115237</ArticleId>
<ArticleId IdType="pmc">PMC7483129</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>BMC Syst Biol. 2014;8 Suppl 4:S11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25521941</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biosci Trends. 2020 Mar 16;14(1):72-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32074550</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Discov. 2020 Mar 18;6:16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32194981</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2001 Dec;7(12):1327-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11726973</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Genome Res. 2003 Nov;13(11):2498-504</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14597658</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Med Genomics. 2008 Oct 09;1:48</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18845002</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Turk J Med Sci. 2020 Apr 17;50(SI-1):620-632</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32299202</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Toxicol. 2015 Nov;89(11):1959-69</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25199682</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Leukoc Biol. 2020 Jul;108(1):323-338</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32083338</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2016 Dec 13;113(50):14408-14413</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27911847</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur Rev Med Pharmacol Sci. 2020 Mar;24(6):3390-3396</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32271456</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharmacol Res. 2020 Jun;156:104808</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32283223</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Drug Saf. 2018 Oct;41(10):919-931</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29858838</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 May 7;382(19):1787-1799</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32187464</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int Rev Immunol. 2011 Feb;30(1):16-34</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21235323</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Toxicol Sci. 2006 Feb;89(2):352-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16221963</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>AIDS. 2003 May 23;17(8):1179-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12819520</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2020 Jul 28;71(15):732-739</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32150618</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Protoc. 2007;2(10):2366-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17947979</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Indian J Pediatr. 2020 Apr;87(4):281-286</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32166607</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Invest. 2011 Sep;121(9):3666-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21841315</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ital Heart J. 2001 Jun;2(6):408-17</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11453575</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biosci Rep. 2019 Apr 17;39(4):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30910847</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Travel Med Infect Dis. 2020 Mar - Apr;34:101663</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32289548</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lupus. 2006;15(5):268-75</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16761500</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2010 Mar 1;184(5):2289-96</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20139273</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharmacol Res. 2020 May;155:104768</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32222346</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Med Sci Monit. 2012 Jun;18(6):CR381-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22648254</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Chin Med Assoc. 2020 Mar;83(3):217-220</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32134861</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biomol Struct Dyn. 2020 Apr 16;:1-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32248766</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nucleic Acids Res. 2019 Jan 8;47(D1):D948-D954</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30247620</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA Netw Open. 2020 Apr 24;3(4):e208857</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32330277</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharmacol Res. 2020 Jun;156:104832</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32304747</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Anaesthesiol Intensive Ther. 2020;52(1):34-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32191830</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Trop Med Int Health. 2020 Mar;25(3):278-280</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32052514</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Regul Homeost Agents. 2020 Mar 14;34(2):327-331</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32171193</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Pharm Res. 2003 Aug;26(8):631-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12967198</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Genet. 2004 Dec;5(12):936-48</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15573125</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>EMBO J. 2003 Jun 2;22(11):2552-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12773372</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pain. 2009 Apr;142(3):275-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19233564</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cardiovasc Ther. 2019 Aug 1;2019:8490707</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31772617</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Environ Res. 2020 May;184:109259</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32143025</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Immunol. 2014 Jan;14(1):9-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24336102</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Jpn Heart J. 2004 Mar;45(2):183-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15090695</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cytokine. 2008 Sep;43(3):402-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18701318</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharmacol Res. 2020 Jun;156:104791</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32302707</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Crit Care. 2020 Jun;57:279-283</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32173110</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Front Endocrinol (Lausanne). 2012 Dec 21;3:170</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23267348</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Environ Health Perspect. 2013 May;121(5):558-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23462649</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2003 Nov;3(11):722-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14592603</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2019 Aug 13;116(33):16410-16419</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31350345</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Infect Dis. 2017 Aug 9;17(1):551</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28793863</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Toxicol. 2020 Feb;94(2):485-494</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31897520</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nucleic Acids Res. 2009 Jul;37(Web Server issue):W305-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19465376</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Respir Res. 2010 Jun 30;11:90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20591166</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Serbie</li>
</country>
</list>
<tree><country name="Serbie"><noRegion><name sortKey="Barali, Katarina" sort="Barali, Katarina" uniqKey="Barali K" first="Katarina" last="Barali">Katarina Barali</name>
</noRegion>
<name sortKey=" Uki Osi, Danijela" sort=" Uki Osi, Danijela" uniqKey=" Uki Osi D" first="Danijela" last=" Uki Osi">Danijela  Uki Osi</name>
<name sortKey=" Ur I, Marijana" sort=" Ur I, Marijana" uniqKey=" Ur I M" first="Marijana" last=" Ur I">Marijana  Ur I</name>
<name sortKey="Antonijevi Miljakovi, Evica" sort="Antonijevi Miljakovi, Evica" uniqKey="Antonijevi Miljakovi E" first="Evica" last="Antonijevi Miljakovi">Evica Antonijevi Miljakovi</name>
<name sortKey="Antonijevi, Biljana" sort="Antonijevi, Biljana" uniqKey="Antonijevi B" first="Biljana" last="Antonijevi">Biljana Antonijevi</name>
<name sortKey="Buha Djordjevic, Aleksandra" sort="Buha Djordjevic, Aleksandra" uniqKey="Buha Djordjevic A" first="Aleksandra" last="Buha Djordjevic">Aleksandra Buha Djordjevic</name>
<name sortKey="Jorgovanovi, Dragica" sort="Jorgovanovi, Dragica" uniqKey="Jorgovanovi D" first="Dragica" last="Jorgovanovi">Dragica Jorgovanovi</name>
<name sortKey="Zivan Evi, Katarina" sort="Zivan Evi, Katarina" uniqKey="Zivan Evi K" first="Katarina" last="Živan Evi">Katarina Živan Evi</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C40 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000C40 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:32920000
   |texte=   Safety assessment of drug combinations used in COVID-19 treatment: in silico toxicogenomic data-mining approach.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:32920000" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidChloroV1

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021

	Serveur d'exploration COVID et hydrochloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration COVID et hydrochloroquine

Safety assessment of drug combinations used in COVID-19 treatment: in silico toxicogenomic data-mining approach.

Safety assessment of drug combinations used in COVID-19 treatment: in silico toxicogenomic data-mining approach.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki